Imran Khan

3.7k total citations · 1 hit paper
37 papers, 1.3k citations indexed

About

Imran Khan is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Imran Khan has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 12 papers in Genetics and 9 papers in Oncology. Recurrent topics in Imran Khan's work include Multiple Myeloma Research and Treatments (19 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Peptidase Inhibition and Analysis (7 papers). Imran Khan is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Peptidase Inhibition and Analysis (7 papers). Imran Khan collaborates with scholars based in United States, Netherlands and Belgium. Imran Khan's co-authors include Tahamtan Ahmadi, Nigel Smith, Ruth E. Cameron, Eric Jones, Dudley S. Finch, Sagar Lonial, Henk M. Lokhorst, A. Kate Sasser, Vikas Nanda and Saad Z. Usmani and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Imran Khan

33 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →

Peers

Countries citing papers authored by Imran Khan

Since Specialization

Citations

This map shows the geographic impact of Imran Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Imran Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Imran Khan more than expected).

Fields of papers citing papers by Imran Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Imran Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Imran Khan. The network helps show where Imran Khan may publish in the future.

Co-authorship network of co-authors of Imran Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Imran Khan. A scholar is included among the top collaborators of Imran Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Imran Khan. Imran Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Screen time exposure and academic performance, anxiety, and behavioral problems among school children 2025 ·PeerJ ·Mohammad Sidiq, Balamurugan Janakiraman, Faizan Kashoo, (unknown), (unknown), Abdullah Alzahrani, (unknown), Arulmani Thiyagarajan, Imran Khan, (unknown), (unknown), (unknown), (unknown), (unknown), Shabnam Khan, Mshari Alghadier	0
2	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma 2024 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Andrew Belch, Torben Plesner, Paul G. Richardson, Jianping Wang, Huaibao Feng, Brendan M. Weiss, Amy Axel, Imran Khan, Hareth Nahi, (unknown), Ajai Chari, Nizar J. Bahlis, Henk M. Lokhorst, A. Kate Sasser, Saad Z. Usmani, Sagar Lonial, Clarissa Uhlar, Tahamtan Ahmadi	0
3	Structural and Dynamic Properties of Allergen and Non-Allergen Forms of Tropomyosin 2018 ·Structure ·(unknown), Douglas H. Pike, Imran Khan, Vikas Nanda	30
4	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma 2018 ·Leukemia & lymphoma ·Shaji Kumar, Brian G.M. Durie, Hareth Nahi, Ravi Vij, Meletios Α. Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Xavier Leleu, Meral Beksaç, Hartmut Goldschmidt, Jens Hillengaß, Zhuo T. Su, Brian Hutton, Chris Cameron, Imran Khan, Annette Lam	5
5	Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma 2018 ·Experimental Hematology and Oncology ·Saad Z. Usmani, Imran Khan, Christopher Chiu, David Foureau, Lawrence J. Druhan, (unknown), Tineke Casneuf, A. Kate Sasser	12
6	Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari, Suzanne Arinsburg, Sundar Jagannath, (unknown), (unknown), (unknown), Gareth J. Morgan, Huaibao Feng, Clarissa Uhlar, Imran Khan, Parul Doshi, Saad Z. Usmani	26
7	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma 2017 ·Blood Advances ·Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser	160
8	Indirect Comparison Of Daratumumab Monotherapy Versus Real-World Historical Control Data In Patients With Multiple Myeloma Who Are Heavily Pre-Treated And Highly Refractory 2016 ·Value in Health ·Joris Diels, Annette Lam, Tetsuro Ito, Yuen Lam Dora Ng, Mandeep R. Mehra, Imran Khan	0
9	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment 2016 ·Clinical Pharmacokinetics ·Pamela L. Clemens, Xiaoyu Yan, Henk M. Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, Richard K. Jansson, Tahamtan Ahmadi, Kristen Lantz, Honghui Zhou, Thomas A. Puchalski, Xu Steven Xu	63
10	Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma 2016 ·Clinical Pharmacology & Therapeutics ·(unknown), Xiaoyu Yan, Thomas A. Puchalski, Sagar Lonial, HM Lokhorst, (unknown), Trine Lindhardt Plesner, Kui Liu, Imran Khan, (unknown), Tahamtan Ahmadi, Juan José Pérez Ruixo, Honghui Zhou, Pamela L. Clemens	48
11	PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 2016 ·Pure Amsterdam UMC ·Tineke Casneuf, Xiuping Xu, (unknown), Amy Axel, Bie Verbist, (unknown), Imran Khan, (unknown), (unknown), Sagar Lonial, Trine Lindhardt Plesner, H M Lokhorst, (unknown), Pamela L. Clemens, A. Kate Sasser	7
12	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma breakdown → 2016 ·Blood ·Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi	303
13	Suprachoroidal haemorrhage following intravitreal injection 2016 ·Postgraduate Medical Journal ·(unknown), Imran Khan, (unknown)	2
14	Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism 2015 ·Thrombosis Research ·Ambarina S. Faiz, Imran Khan, Michele G. Beckman, Paula Bockenstedt, John A. Heit, Roshni Kulkarni, Marilyn J. Manco‐Johnson, Stephan Moll, Thomas L. Ortel, Claire S. Philipp	27
15	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) Treatment 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Pamela L. Clemens, Xiaoyu Yan, Thomas A. Puchalski, H M Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, (unknown), (unknown), (unknown), Huifen Zhou, (unknown)	2
16	Self-Assembly of Left- and Right-Handed Molecular Screws 2013 ·Journal of the American Chemical Society ·Fei Xu, Imran Khan, (unknown), Avanish Singh Parmar, Teresita Silva, N. Sanjeeva Murthy, Vikas Nanda	55
17	Simultaneous Spectrophotometric Estimation of Abacavir sulphate in Tablet Dosage Form 2010 ·Archives of applied science research ·(unknown), Imran Khan, (unknown), (unknown), (unknown), (unknown)	1
18	Quantitative analysis of glycyrrhizic acid in crude drug and its herbal formulation by UV Spectrophotometry 2010 ·Archives of applied science research ·(unknown), Imran Khan, Paramasivan T. Perumal, (unknown), (unknown)	4
19	Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part II: in vivo investigation 2004 ·Biomaterials ·Imran Khan, Nigel Smith, Eric Jones, Dudley S. Finch, Ruth E. Cameron	91
20	Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part I: materials selection and evaluation 2004 ·Biomaterials ·Imran Khan, Nigel Smith, Eric Jones, Dudley S. Finch, Ruth E. Cameron	136

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact